New hope for liver cancer: drug combo trial launches
NCT ID NCT05441475
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests a new drug, ABSK-011, combined with the immunotherapy atezolizumab (or standard care) in 118 people with advanced or unresectable hepatocellular carcinoma, a type of liver cancer. The study aims to see if the combination is safe and can shrink tumors. Participants must have a specific genetic marker (FGF19 overexpression) and have not had prior systemic therapy.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ABSK-011 (a targeted cancer drug) combined with atezolizumab (an immunotherapy) or standard care
What this could lead to
If successful, this combination could offer a new treatment option for people with advanced liver cancer that has not responded to other therapies.
What could go wrong
This is an early-phase trial with a small number of participants, so results may not apply to everyone. Side effects from the drug combination could be serious.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Tongji Hospital affiliated to Tongji Medical College of Huazhong University of Science & Technology
Hubei, Shanghai Municipality, 430030, China